“djuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Read full-text medical journal articles from Medscape's Gallbladder and Biliary Tract Disease News.

The approval of Ziihera extends across European Union (EU) member states along with Norway, Iceland and Liechtenstein. The EC's decision marks Ziihera as the first conditionally a ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz ...

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China, addressing a significant unmet medical need in this patient population.

Fujifilm Pharma’s liposomal formulation of gemcitabine FF-10832 receives US FDA’s orphan drug designation to treat biliary tract cancer: Cambridge, Massachusetts Wednesday, Ju ...

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...